Roles of Oxidants,Nitric Oxide,and Asymmetric Dimethylarginine in Endothelial Function

Abstract

Vascular endothelium plays a crucial role in ensuring normal function and morphology of blood vessels, and many risk factors of atherosclerosis act via their effects on endothelial cells. However, endothelial dysfunction is induced by very different pathomechanisms. In principle, it is caused by an impaired bioavailability of nitric oxide (NO) due to an inhibited synthesis (eg, by asymmetric dimethylarginine [ADMA]) or increased consumption of formed NO (by reactive oxygen species [ROS]). ROS can be synthesized in the organism (eg, by different enzymes) or can be administered from the environment (eg, by cigarette smoking), whereas ADMA is the subject of endogenous metabolism only. Many studies have elucidated the system of pathomechanisms and targeted some as potential goals for therapeutic interventions. This review demonstrates roles of ROS, NO, ADMA, endothelin, and estrogen in endothelial function and dysfunction focusing on homocysteinemia and diabetes mellitus and provide examples for the medical treatment of endothelial dysfunction.

Keywords

endothelium oxidants nitric oxide atherosclerosis homocysteinemia diabetes mellitus

References

Tunstall-Pedoe H. , Kuulasmaa K. , Amouyel P. , Arveiler D. , Rajakangas AM , Pajak A. , for the WHO Monica Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation . 1994;90:583-612.

Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.

Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med. 1999;340:115-126.

Ruef J. , Peter K. , Nordt TK , Runge MS , Kübler W. , Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost . 1999;82(suppl):32-37.

Steinberg D. Lewis A. Conner memorial lecture. Oxidative modification of LDL and atherogenesis. Circulation. 1997 ;95:1062-1071.

Giannotti G. , Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007;32:568-572.

Lerman A. , Zeiher AM Endothelial function. Cardiac events. Circulation . 2005;111:363-368.

Maturana MA , Irigoyen MC , Spritzer PM Menopause, estrogens, and endothelial dysfunction: current concepts . Clinics. 2007;62:77-86.

Endemann DH , Schiffrin EL Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983-1992.

10.

Landmesser U. , Hornig B. , Drexler H. Endothelial function. A critical determinant in atherosclerosis? Circulation. 2004;109(suppl II):1127-1133.

11.

Vapaatalo H. , Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit. 2001;7:1075-1085.

12.

Brunner H. , Cockroft JR , Deanfield J. , et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension . J Hypertens. 2005;23:233-246.

13.

Duvall WL Endothelial dysfunction and antioxidants. Mt Sinai J Med. 2005;72:71-80.

14.

Dzau VJ , Bernstein K. , Celermajer D. , et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Tissue angiotensin-converting enzyme: Biology, function, and pathophysiology. Am J Cardiol. 2001;88(suppl):1L-20L.

15.

Davignon J. , Ganz P. Role of endothelial dysfunction in atherosclerosis . Circulation. 2004;109(suppl 1):11127-11132.

16.

Kublickiene K. , Luksha L. Gender and the endothelium. Pharmacol Rep. 2008;60:49-60.

17.

Stankevicius E. , Kevelaitis E. , Vainorius E. , Simonsen U. Role of nitric oxide and other endothelium-derived factors. Medicina. 2003;39:333-341.

18.

Tostes RC , Nigro D. , Fortes ZB , Carvalho MHC. Effects of estrogen on the vascular system. Braz J Med Biol Res. 2003;36:1143-1158.

19.

Abraham D. , Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther. 2007 ;9(suppl 2):S2.

20.

Rich S. , McLaughlin VV Endothelin receptor blockers in cardiovascular disease. Circulation . 2003;108:2184-2190.

21.

Liao JK Endothelium and acute coronary syndromes. Clin Chem . 1998;44:1799-1808.

22.

Maytin M. , Leopold J. , Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep. 1999;1:156-164.

23.

Salonen JT , Nyyssönen K. , Salonen R. , et al. Lipoprotein oxidation and progression of carotid atherosclerosis . Circulation. 1997;95:840-845.

24.

Siekmeier R. , Steffen C. , März W. Role of oxidants and antioxidants in atherosclerosis - results of in vitro and in vivo investigations . J Cardiovasc Pharmacol Therapeut. 2007;12:265-282.

25.

Libby P. Inflammation in atherosclerosis. Nature. 2002 ;420:868-874.

26.

Libby P. , Ridker PM , Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.

27.

Harrison DG Endothelial control of vasomotion and nitric oxide production: a potential target for risk factor management. Cardiol Clin. 1996;14:1-15.

28.

Qian H. , Neplioueva V. , Shetty GA , Channon KM , George SE Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation. 1999;99:2979-2982.

29.

Dudzinski DM , Igarashi J. , Greif D. , Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol. 2006;46:235-276.

30.

Pou S. , Pou WS , Bredt DS , Snyder SH , Rosen GM Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem. 1992;267:24173-24176.

31.

Vasquez-Vivar J. , Kalyanaraman B. , Martásek P. , et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA. 1998;95:9220-9225.

32.

Moens AL , Kass DA Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2006;26: 2439-2444.

33.

Gornik HL , Creager MA Arginine metabolism: enzymology, nutrition, and clinical significance. Arginine and endothelial and vascular health. J Nutr. 2004;134: 2880S-2887S.

34.

Harrison DG Perspective series: nitric oxide and nitric oxide synthases. Cellular and molecular mechanisms of endothelial cell dysfunction . J Clin Invest. 1997;100: 2153-2157.

35.

Cai H. , Harrison DG Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress . Circ Res. 2000;87:840-844.

36.

Landmesser U. , Harrison DG Oxidant stress as a marker for cardiovascular events. Ox marks the spot. Circulation. 2001 ;104:2638-2640.

37.

Sorescu D. , Weiss D. , Lassegue B. , et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation. 2002 ;105:1429-1435.

38.

Gryglewski RJ , Palmer RM , Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor . Nature. 1986;320:454-456.

39.

Böger R.H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the ``L-arginine paradox'' and acts as a novel cardiovascular risk factor. J Nutr. 2004;134:2842S-2847S.

40.

Cooke J. P. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037.

41.

Alp NJ , Channon KM Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:413-420.

42.

d'Uscio LV , Milstien S. , Richardson D. , Smith L. , Katusic ZS Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res. 2003;92:88-95.

43.

Kawashima S. , Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:998-1005.

44.

Kawashima S. Malfunction of vascular control in lifestyle-releated diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis . J Pharmacol Sci. 2004;96:411-419.

45.

Landmesser U. , Dikalov S. , Price SR , et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209.

46.

Laursen JB , Somers M. , Kurz S. , et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin . Circulation. 2001;103:1282-1288.

47.

Madamanchi NR , Vendrov A. , Runge MS Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29-38.

48.

Tiefenbacher CP , Bleeke T. , Vahl C. , Amann K. , Vogt A. , Kübler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis . Circulation. 2000;102:2172-2179.

49.

Tiefenbacher C. Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial dysfunction? Am J Physiol Heart Circ Physiol. 2001;280: H2484-H2488.

50.

Vasquez-Vivar J. , Duquaine D. , Whitsett J. , Kalyanaraman B. , Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol. 2002;22: 1655-1661.

51.

Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J. 2002;66:529-533.

52.

Tsuchiya M. , Asada A. , Kasahara E. , Sato EF , Shindo M. , Inoue M. Smoking a single cigarette rapidly reduces combined concentrations of nitrate and nitrite and concentrations of antioxidants in plasma. Circulation. 2002;105:1155-1157.

53.

Griendling KK , Sorescu D. , Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.

54.

Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47-95.

55.

Dupont GP , Huecksteadt TP , Marshall BC , Ryan US , Michael JR , Hoidal JR Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial cells. J Clin Invest. 1992;89:197-202.

56.

Nakazono K. , Watanabe N. , Matsuno K. , Sasaki J. , Sato T. , Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA. 1991 ;88: 10045-10048.

57.

Suzuki H. , Swei A. , Zweifach BW , Schmid-Schönbein GW In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats. Hydroethidine microfluorography. Hypertension . 1995;25: 1083-1089.

58.

Ohara Y. , Peterson TE , Harrison DG Hypercholesterolemia increases endothelial superoxide anion production . J Clin Invest. 1993;91:2546-2551.

59.

Ohara Y. , Peterson TE , Sayegh HS , Subramanian RR , Wilcox JN , Harrison DG Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation. 1995;92:898-903.

60.

Pagano PJ , Chanock SJ , Siwik DA , Colucci WS , Clark JK Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension . 1998;32: 331-337.

61.

Berry C. , Hamilton CA , Brosnan MJ , et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000;101:2206-2212.

62.

Barry-Lane PA , Patterson C. , van der Merwe M. , et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest. 2001;108:1513-1522.

63.

Touyz RM , Chen X. , Tabet F. , et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002;90:1205-1213.

64.

Griendling KK , Minieri CA , Ollerenshaw JD , Alexander RW Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res . 1994;74:1141-1148.

65.

Diep QN , Amiri F. , Touyz RM , et al. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002 ;40:866-871.

66.

Diep QN , El Mabrouk M. , Cohn JS , et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation. 2002;105:2296-2302.

67.

Rajagopalan S. , Kurz S. , Münzel T. , et al. Angiotensin IImediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.

68.

Touyz RM , Schiffrin EL Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension. 1999;34(Part 2):976-982.

69.

Holland JA , Meyer JW , Chang MM , O'Donnell RW , Johnson DK , Ziegler LM Thrombin stimulated reactive oxygen species production in cultured human endothelial cells. Endothelium. 1998 ;6:113-121.

70.

Görlach A. , Diebold I. , Schini-Kerth VB , et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22phoxcontaining NADPH oxidase. Circ Res. 2001;89:47-54.

71.

Herkert O. , Diebold I. , Brandes RP , Hess J. , Busse R. , Görlach A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation . 2002;105:2030-2036.

72.

Patterson C. , Ruef J. , Madamanchi NR , et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47phox may participate in forming this oxidase in vitro and in vivo. J Biol Chem. 1999;274:19814-19822.

73.

Marumo T. , Schini-Kerth VB , Fisslthaler B. , Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-κB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation . 1997;96:2361-2367.

74.

Görlach A. , Brandes RP , Bassus S. , et al. Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets. FASEB J. 2000;14:1518-1528.

75.

Kreuzer J. , Viedt C. , Brandes RP , et al. Platelet-derived growth factor activates production of reactive oxygen species by NAD(P)H-oxidase in smooth muscle cells through Gi1,2. FASEB J. 2003;17:38-40.

76.

De Keulenaer GW , Alexander RW , Ushio-Fukai M. , Ishizaka N. , Griendling KK Tumour necrosis factor α activates a p22phox-based NADH oxidase in vascular smooth muscle . Biochem J. 1998;329:653-657.

77.

Nwariaku FE , Liu Z. , Zhu X. , et al. NADPH oxidase mediates vascular endothelial cadherin phosphorylation and endothelial dysfunction . Blood . 2004;104:3214-3220.

78.

Gertzberg N. , Neumann P. , Rizzo V. , Johnson A. NAD(P)H oxidase mediates the endothelial barrier dysfunction by TNF-α. Am J Physiol Lung Cell Mol Physiol . 2004;286:L37-L48.

79.

Shinozaki K. , Nishio Y. , Okamura T. , et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res. 2000;87:566-573.

80.

Werner ER , Gorren ACF , Heller R. , Werner-Felmayer G. , Mayer B. Tetrahydrobiopterin and nitric oxide: mechanistic and pharmacological aspects . Exp Biol Med. 2003;228:1291-1302.

81.

Beltowski J. , Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep. 2006;58:159-178.

82.

Kielstein JT , Frölich JC , Haller H. , Fliser D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant. 2001;16:1742-1745.

83.

Böger RH , Ron ES L-arginine improves vascular function by overcoming the deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev . 2005;10:14-23.

84.

Vallance P. , Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24:1023-1030.

85.

Reddy MA , Thimmalapura PR , Lanting L. , Nadler JL , Fatima S. , Natarajan R. The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation. Mediation of angiotensin II effects. J Biol Chem. 2002;277:9920-9928.

86.

Reddy MA , Kim YS , Lanting L. , Natarajan R. Reduced growth factor responses in vascular smooth muscle cells derived from 12/15-lipoxygenase-deficient mice. Hypertension. 2003;41:1294-1300.

87.

Cyrus T. , Witztum JL , Rader DJ , et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 1999 ;103:1597-1604.

88.

Boveris A. , Cadenas E. , Stoppani AOM Role of ubiquinone in the mitochondrial generation of hydrogen peroxide . Biochem J. 1976;156:435-444.

89.

Ballinger SW , Patterson C. , Yan CN , et al. Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ Res. 2000;86:960-966.

90.

Ballinger SW , Patterson C. , Knight-Lozano CA , et al. Mitochondrial integrity and function in atherogenesis. Circulation. 2002;106:544-549.

91.

Stralin P. , Karlsson K. , Johansson BO , Marklund SL The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol. 1995;15:2032-2036.

92.

Fukai T. , Siegfried MR , Ushio-Fukai M. , Cheng Y. , Kojda G. , Harrison DG Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest. 2000 ;105:1631-1639.

93.

Landmesser U. , Merten R. , Spiekermann S. , Büttner K. , Drexler H. , Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2000;101:2264-2270.

94.

Spiekermann S. , Landmesser U. , Dikalov S. , et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003;107:1383-1389.

95.

Böger RH , Bode-Böger SM , Szuba A. , et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.

96.

Chan NN , Chan Jcn. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia. 2002;45:1609-1616.

97.

Nijveldt RJ , Siroen MPC , Teerlink T. , van Leeuwen PAM Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure ? J Nutr. 2004;134: 2848S-2852S.

98.

Osanai T. , Saitoh M. , Sasaki S. , Tomita H. , Matsunaga T. , Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension. 2003;42:985-990.

99.

Xiao S. , Wagner L. , Schmidt RJ , Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int. 2001 ;59:1466-1472.

100.

Kielstein JT , Bode-Böger SM , Frölich JC , Ritz E. , Haller H. , Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation. 2003;107:1891-1895.

101.

Kielstein JT , Impraim B. , Simmel S. , et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans . Circulation. 2004;109:172-177.

102.

Eldibany MM , Caprini JA Hyperhomocysteinemia and thrombosis . Arch Pathol Lab Med. 2007;131:872-884.

103.

Hayden MR , Tyagi SC Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation . Nutr J. 2004;3:4.

104.

Austin RC , Lentz SR , Werstuck GH Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004;11: S56-S64.

105.

Brown AA , Hu FB Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr. 2001;73:673-686.

106.

Dhillon B. , Badiwala MV , Maitland A. , Rao V. , Li SH , Verma S. Tetrahydrobiopterin attenuates homocysteine induced endothelial function. Mol Cell Biochem. 2003;247:223-227.

107.

Topal G. , Brunet A. , Millanvoye E. , et al. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol. Med. 2004;36:1532-1541.

108.

Zhang X. , Li H. , Jin H. , Ebin Z. , Brodsky S. , Goligorsky MS Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol. 2000;279:F671-F678.

109.

Virdis A. , Ghiadoni L. , Cardinal H. , et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol. 2001;38:1106-1115.

110.

Virdis A. , Iglarz M. , Neves MF , et al. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1352-1357.

111.

Böger RH , Lentz SR , Bode-Böger SM , Knapp HR , Haynes WG Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci. (Lond). 2001;100:161-167.

112.

Stühlinger MC , Tsao PS , Her JH , Kimoto M. , Balint RF , Cooke JP Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation . 2001;104:2569-2575.

113.

Stühlinger MC , Oka RK , Graf EE , et al. Endothelial dysfunction induced hyperhomocyst(e)inemia: role of asymmetric dimethylarginine . Circulation. 2003;108: 933-938.

114.

Stühlinger MC , Stanger O. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction . Curr Drug Metab. 2005;6:3-14.

115.

Mallamaci F. , Zoccali C. , Tripepi G. , et al, and CREED Investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients . Kidney Int. 2002 ;61:609-614.

116.

Zoccali C. , Mallamaci F. , Tripepi G. Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD). Eur J Clin Pharmacol. 2006;62(suppl 1):131-135.

117.

Boushey CJ , Beresford SA , Omenn GS , Motulsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.

118.

The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA. 2002;288:2015-2022.

119.

Wald DS , Law M. , Morris JK Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis . BMJ. 2002;325:1202.

120.

Bazzano LA , Reynolds K. , Holder KN , He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials . JAMA. 2006;296:2720-2726.

121.

Wald DS , Morris JK , Law M. , Wald NJ Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ. 2006;333:1114-1117.

122.

Jacques PF , Bostom AG , Williams RR , et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.

123.

Yang Q. , Botto LD , Erickson JD , et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation. 2006;113:1335-1343.

124.

Hiltunen MO , Ylä-Herttuala S. DNA methylation, smooth muscle cells, and atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23:1750-1753.

125.

Lin KY , Ito A. , Asagami T. , et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987-992.

126.

De Vriese AS , Verbeuren TJ , Van de Voorde J. , Lameire NH , Vanhoutte PM Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-974.

127.

Evans JL , Goldfine ID , Maddux BA , Grodsky GM Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599-622.

128.

Montagnani M. , Chen H. , Barr VA , Quon MJ Insulin-stimulated activation of eNOS is dependent of Ca2+ but requires phosphorylation by Akt at Ser1179. J Biol Chem. 2001;276:30392-30298.

129.

Montagnani M. , Ravichandran LV , Chen H. , Esposito DL , Quon MJ Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol . 2002;16: 1931-1942.

130.

Wautier JL , Schmidt AM Protein glycation. A firm link to endothelial cell dysfunction. Circ Res. 2004;95:233-238.

131.

Du XL , Edelstein D. , Dimmeler S. , Ju Q. , Sui C. , Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by translational modification at the Akt site. J Clin Invest . 2001;108:1341-1348.

132.

Xu B. , Chibber R. , Ruggiero D. , Kohner E. , Ritter J. , Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 2003;17:1289-1291.

133.

Xu B. , Ji Y. , Yao K. , Cao YX , Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance of diabetes. Clin Sci. 2005;109:439-446.

134.

Kunisaki M. , Bursell SE , Umeda F. , Nawata H. , King GL Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels . Diabetes . 1994;43:1372-1377.

135.

Kunisaki M. , Bursell SE , Clermont AC , et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway . Am J Physiol. 1995;269:E239-E246.

136.

Uhlmann S. , Rezzoug K. , Friedrichs U. , Hoffmann S. , Wiedemann P. Advanced glycation end products quench nitric oxide in vitro. Graefe's Arch Clin Exp Ophthalmol. 2002;240:860-866.

137.

Anderson TJ Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev. 2003;8:71-86.

138.

Hadi HAR , Suwaidi JA Endothelial dysfunction in diabetes mellitus . Vasc Health Risk Manag. 2007;3: 853-876.

139.

Bissessor N. , White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc Health Risk Manag. 2007;3:425-430.

140.

Hammoud RA , Vaccari CS , Nagamia SH , Khan BV Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag. 2007;3:937-945.

141.

HOPE. The HOPE (Heart Outcomes Prevention Evaluation) Study : The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators . Can J Cardiol. 1996;12:127-137.

142.

Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan . Vasc Health Risk Manag. 2008;4:89-101.

143.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.

144.

Gabbay E. , Fraser J. , McNeil K. Review of bosentan in the management of pulmonary arterial hypertension . Vasc Health Risk Manag. 2007;3:887-900.

145.

Raja SG , Dreyfus GD Current status of bosentan for treatment of pulmonary hypertension . Ann Card Anaesth. 2008;11:6-14.

146.

Martens Fmac , Rabelink TJ , op't Roodt J. , de Koning EJP , Visseren FLJ. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone . Eur Heart J. 2006;27:1605-1609.

147.

Matsumoto T. , Kobayashi T. , Kamata K. Hirosi Kuriyama Award 2007 Memorial Review. Relationships among ET-1, PPAR-gamma, oxidative stress and endothelial dysfunction in diabetic animals. J Smooth Muscle Res. 2008;44:41-55.

148.

Steinberg HO , Brechtel G. , Johnson A. , Fineberg N. , Baron AD Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:1172-1179.

149.

Zeng G. , Quon MJ Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest . 1996;98:894-898.

150.

Zeng G. , Nystrom FH , Ravichandran LV , et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539-1545.

151.

Pahan K. Lipid-lowering drugs. Cell Mol Life Sci. 2006 ;63:1165-1178.

152.

Bellamy MF , McDowell IF , Ramsey MW , Brownlee M. , Newcombe RG , Lewis MJ Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest. 1999;29:659-662.

153.

Chao CL , Chien KL , Lee YT Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia . Am J Cardiol. 1999;84: 1359-1361.

154.

Title LM , Cummings PM , Giddens K. , Genest JJ , Nassar BA Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. Am J Cardiol. 2000;36:758-765.

155.

Woo KS , Chook P. , Lolin YI , Sanderson JE , Metreweli C. , Celermajer DS Folic acid improves arterial endothelial function in adults with hyperhomocystinemia . J Am Coll Cardiol. 1999;34:2002-2006.

156.

Doshi SN , McDowell IF , Moat SJ , et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol. 2001;21: 1196-1202.

157.

Stroes ESG , van Faassen EE , Yo M. , et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res . 2000;86:1129-1134.

158.

Heitzer T. , Brockhoff C. , Mayer B. , et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:e36-e41.

159.

Heitzer T. , Krohn K. , Albers S. , Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia. 2000;43: 1435-1438.

160.

Verma S. , Lovren F. , Dumont AS , et al. Tetrahydrobiopterin improves endothelial function in human saphenous veins. J Thorac Cardiovasc Surg. 2000;120:668-671.

161.

Böger RH The pharmacodynamics of L-arginine. J Nutr. 2007;137:1650S-1655S.

162.

Wilson AM , Harada R. , Nair N. , Balasubramanian N. , Cooke JP L-Arginine supplementation in peripheral arterial disease. Circulation. 2007;116:188-195.